Przejdź do
Wybierz wielkość
| Rozmiar/SKU | Dostępność | Cena netto |
|---|
Informacje o tej pozycji
grade
pharmaceutical primary standard
agency
USP
API family
doxepin
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
pharmaceutical
format
neat
SMILES string
O1Cc2c(cccc2)C(=O)c3c1cccc3
InChI
1S/C14H10O2/c15-14-11-6-2-1-5-10(11)9-16-13-8-4-3-7-12(13)14/h1-8H,9H2
InChI key
YUSHFLBKQQILNV-UHFFFAOYSA-N
General description
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Also, for use with USP monograph such as Doxepin Hydrochloride
Analysis Note
Other Notes
1 of 1
Ta pozycja | |||
|---|---|---|---|
| description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard | description United States Pharmacopeia (USP) Reference Standard | description - |
| manufacturer/tradename USP | manufacturer/tradename USP | manufacturer/tradename USP | manufacturer/tradename - |
| grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade pharmaceutical primary standard | grade pharmaceutical secondary standard, certified reference material |
| application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) | application(s) pharmaceutical (small molecule) | application(s) pharmaceutical |
| format neat | format neat | format neat | format - |
| API family doxepin | API family doxepin | API family doxepin | API family doxepin |
| agency USP | agency USP | agency USP | agency traceable to USP 1225533 |
Słowo ostrzegawcze
Danger
Kody zagrożeń
Ostrzeżenia
Hazard Classifications
Acute Tox. 3 Oral
Klasa składowania
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
Temperatura zapłonu (°F)
Not applicable
Temperatura zapłonu (°C)
Not applicable
Wybierz jedną z najnowszych wersji:
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.


